Inositol niacinate

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 598928

CAS#: 6556-11-2

Description: Inositol niacinate is a peripheral vasodilator.

Chemical Structure

img
Inositol niacinate
CAS# 6556-11-2
Instruction

Theoretical Analysis

MedKoo Cat#: 598928
Name: Inositol niacinate
CAS#: 6556-11-2
Chemical Formula: C42H30N6O12
Exact Mass: 810.19
Molecular Weight: 810.730
Elemental Analysis: C, 62.22; H, 3.73; N, 10.37; O, 23.68

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Inositol niacinate; NSC 49506; NSC-49506; NSC49506; Mesonex; Dilexpal; Dilcit; Palohex;

IUPAC/Chemical Name: cyclohexane-1,2,3,4,5,6-hexayl hexanicotinate

InChi Key: MFZCIDXOLLEMOO-UHFFFAOYSA-N

InChi Code: InChI=1S/C42H30N6O12/c49-37(25-7-1-13-43-19-25)55-31-32(56-38(50)26-8-2-14-44-20-26)34(58-40(52)28-10-4-16-46-22-28)36(60-42(54)30-12-6-18-48-24-30)35(59-41(53)29-11-5-17-47-23-29)33(31)57-39(51)27-9-3-15-45-21-27/h1-24,31-36H

SMILES Code: O=C(c1cnccc1)OC2C(OC(c3cnccc3)=O)C(OC(c4cnccc4)=O)C(OC(c5cnccc5)=O)C(OC(c6cnccc6)=O)C2OC(c7cnccc7)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 810.73 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Dib JG, Dedeyan S. Purported benefits of inositol niacinate. Am J Health Syst Pharm. 2004 Feb 1;61(3):307-8. PubMed PMID: 14986567.

2: Heather AJ. The use of Hexanicotol (inositol niacinate) in peripheral vascular disease. Del Med J. 1967 Feb;39(2):33-8. PubMed PMID: 5341473.

3: Poon IO, Chow DS, Liang D. Dissolution profiles of nonprescription extended-release niacin and inositol niacinate products. Am J Health Syst Pharm. 2006 Nov 1;63(21):2128-34. PubMed PMID: 17057051.

4: Mishima Y, Kamiya K, Sakaguchi S, Kusaba A, Sakuma A. A multiclinic double-blind trial of pyridinolcarbamate and inositol niacinate in ischemic ulcer due to chronic arterial occlusion. Angiology. 1977 Feb;28(2):84-94. PubMed PMID: 326097.

5: LUMISH SH, BLYN C, NODINE JH. Inositol niacinate as a peripheral vasodilator. Curr Ther Res Clin Exp. 1962 May;4:243-8. PubMed PMID: 14467334.

6: Milton SG, Robinson K, Ma J, Wei B, Poon IO, Liang D. Biotransformation and pharmacokinetics of inositol hexanicotinate in rats. Xenobiotica. 2013 Sep;43(9):817-22. doi: 10.3109/00498254.2012.762591. Epub 2013 Jan 24. PubMed PMID: 23347001.

7: Keenan JM. Wax-matrix extended-release niacin vs inositol hexanicotinate: a comparison of wax-matrix, extended-release niacin to inositol hexanicotinate "no-flush" niacin in persons with mild to moderate dyslipidemia. J Clin Lipidol. 2013 Jan-Feb;7(1):14-23. doi: 10.1016/j.jacl.2012.10.004. Epub 2012 Oct 30. PubMed PMID: 23351578.

8: Squires H, Simpson E, Meng Y, Harnan S, Stevens J, Wong R, Thomas S, Michaels J, Stansby G. A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Technol Assess. 2011 Dec;15(40):1-210. doi: 10.3310/hta15400. Review. PubMed PMID: 22142554; PubMed Central PMCID: PMC4781353.

9: Liang D, Ma J, Wei B, Poon IO, Bell EC, Bates TR. Determination of inositol hexanicotinate in rat plasma by high performance liquid chromatography with UV detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 Feb 15;863(1):172-6. doi: 10.1016/j.jchromb.2007.12.024. Epub 2008 Jan 4. PubMed PMID: 18207467.

10: Kiff RS, Quick CR. Does inositol nicotinate (Hexopal) influence intermittent claudication? A controlled trial. Br J Clin Pract. 1988 Apr;42(4):141-5. PubMed PMID: 3061427.

11: Head A. Treatment of intermittent claudication with inositol nicotinate. Practitioner. 1986 Jan;230(1411):49-54. PubMed PMID: 3513149.

12: O'Hara J, Jolly PN, Nicol CG. The therapeutic efficacy of inositol nicotinate (Hexopal) in intermittent claudication: a controlled trial. Br J Clin Pract. 1988 Sep;42(9):377-83. PubMed PMID: 3075929.

13: Inositol hexaniacinate. Altern Med Rev. 1998 Jun;3(3):222-3. PubMed PMID: 9630739.

14: Inositol nicotinate in intermittent claudication. Practitioner. 1986 Jun;230(1416):506-9. PubMed PMID: 3748967.

15: WELSH AL, EDE M. Inositol hexanicotinate for improved nicotinic acid therapy. Preliminary report. Int Rec Med. 1961 Jan;174:9-15. PubMed PMID: 13784278.

16: CHITI W. [APROPOS OF THE GASTROINTESTINAL ABSORPTION OF INOSITOL HEXANICOTINATE]. Farmaco Prat. 1964 Aug;19:378-84. Italian. PubMed PMID: 14177540.

17: Ring EF, Porto LO, Bacon PA. Quantitative thermal imaging to assess inositol nicotinate treatment for Raynaud's syndrome. J Int Med Res. 1981;9(6):393-400. PubMed PMID: 7319129.

18: BRANZI G, ANNINO G. [Therapy of peripheral arteriopathies with a compound with a base of inositol hexanicotinate]. Riforma Med. 1963 Jan 19;77:60-6. Italian. PubMed PMID: 14014996.

19: HAMILTON RR. Speripheral vascular disease in general practice. Some experiences with meso-inositol-hexanicotinate. Practitioner. 1960 Mar;184:367-9. PubMed PMID: 14399278.

20: NAKAZAWA T, KABESHIMA A, SAITO M, UUCHI Y, NAKAHARA M. [CLINICAL TRIAL OF A NEW NICOTINIC ACID DERIVATIVE, MESO-INOSITOL-HEXANICOTINATE, IN NEUROPSYCHIATRY]. No To Shinkei. 1963 Sep;15:902-9. Swedish. PubMed PMID: 14045318.